VIR Vir Biotechnology Inc
Price (delayed)
$7.98
Market cap
$1.09B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.58
Enterprise value
$874.59M
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are
Highlights
The debt has contracted by 19% YoY and by 13% from the previous quarter
VIR's gross margin is up by 5% year-on-year
The net income has dropped by 84% year-on-year but it has increased by 10% since the previous quarter
The EPS has dropped by 83% year-on-year but it rose by 11% since the previous quarter
VIR's revenue has plunged by 84% YoY
The company's gross profit has shrunk by 83% YoY
Key stats
What are the main financial stats of VIR
Market
Valuations
Earnings
Shares outstanding
136.64M
Market cap
$1.09B
Enterprise value
$874.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
13.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.09
Revenue
$78.88M
EBIT
-$492.27M
EBITDA
-$468.26M
Free cash flow
-$457.87M
Per share
Balance sheet
Liquidity
EPS
-$3.58
Free cash flow per share
-$3.36
Book value per share
$10.54
Revenue per share
$0.58
TBVPS
$11.99
Total assets
$1.67B
Total liabilities
$235.89M
Debt
$95.02M
Equity
$1.43B
Working capital
$1.11B
Debt to equity
0.07
Current ratio
12.51
Quick ratio
12.08
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-593.7%
Gross margin
98.8%
Net margin
-612.4%
Operating margin
-715.6%
Return on assets
-26%
Return on equity
-30.9%
Return on invested capital
-33%
Return on capital employed
-31.3%
Return on sales
-624.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIR stock price
How has the Vir Biotechnology stock price performed over time
Intraday
0.63%
1 week
1.92%
1 month
-7.42%
1 year
-17.13%
YTD
-20.68%
QTD
-10.34%
Financial performance
How have Vir Biotechnology's revenue and profit performed over time
Revenue
$78.88M
Gross profit
$77.93M
Operating income
-$564.46M
Net income
-$483.04M
Gross margin
98.8%
Net margin
-612.4%
The net income has dropped by 84% year-on-year but it has increased by 10% since the previous quarter
VIR's revenue has plunged by 84% YoY
The company's gross profit has shrunk by 83% YoY
The company's operating income has shrunk by 80% YoY but it rose by 9% QoQ
Growth
What is Vir Biotechnology's growth rate over time
Valuation
What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
0.76
P/S
13.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.09
The EPS has dropped by 83% year-on-year but it rose by 11% since the previous quarter
VIR's price to book (P/B) is 81% lower than its 5-year quarterly average of 3.9 and 6% lower than its last 4 quarters average of 0.8
Vir Biotechnology's equity has decreased by 21% YoY and by 7% from the previous quarter
VIR's revenue has plunged by 84% YoY
The price to sales (P/S) is 68% lower than the 5-year quarterly average of 42.2 and 7% lower than the last 4 quarters average of 14.7
Efficiency
How efficient is Vir Biotechnology business performance
Vir Biotechnology's return on assets has shrunk by 157% YoY but it has increased by 3.7% QoQ
Vir Biotechnology's return on equity has shrunk by 136% YoY but it has increased by 5% QoQ
The return on invested capital has dropped by 75% year-on-year but it rose by 9% since the previous quarter
The return on sales rose by 10% since the previous quarter
Dividends
What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIR.
Financial health
How did Vir Biotechnology financials performed over time
VIR's quick ratio is up by 46% year-on-year but it is down by 2.3% since the previous quarter
The company's total liabilities fell by 46% YoY and by 4.4% QoQ
The debt is 93% less than the equity
Vir Biotechnology's equity has decreased by 21% YoY and by 7% from the previous quarter
The debt has contracted by 19% YoY and by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.